VIR - Spark Newswire

2 minute read

Vir Biotechnology Announces First Patient Dosed In The Phase 2 SOLSTICE Trial Evaluating VIR-2218 And VIR-3434 For The Treatment Of Chronic Hepatitis D Virus Infection

September 22, 8:01 AM

Vir Biotechnology, Inc. (NASDAQ:VIR) today announced that the first patient has been dosed in the Phase 2 SOLSTICE clinical trial evaluating VIR-2218 and VIR-3434 as monotherapy and in combination for the treatment of

VIR

1 minute read

This Hepatitis Stock Has ‘Multiple Paths To Value Creation,’ Expects To Double, Bullish Analyst Predicts

By Vandana Singh

September 14, 2:11 PM

SVB Leerink initiated coverage on Vir Biotechnology Inc (NASDAQ:VIR) with an Outperform rating and a price target of $40, with an investment…

VIR

12 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For September 14, 2022

By Benzinga Insights

September 14, 10:07 AM

Upgrades For Iris Energy Ltd (NASDAQ:IREN), Compass Point upgraded the previous rating of Neutral to Buy. The current stock performance of Iris Energy shows a 52-week-high of $17.97 and a 52-week-low of $2.89. Moreover, at the end of the last trading period, the closing price was at $4.26.

AGL

1 minute read

SVB Leerink Initiates Coverage On Vir Biotechnology with Outperform Rating, Announces Price Target of $40

By Benzinga Newsdesk

September 14, 6:54 AM

SVB Leerink analyst Roanna Ruiz initiates coverage on Vir Biotechnology (NASDAQ:VIR) with a Outperform rating and announces Price Target of $40.

VIR

12 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For September 9, 2022

By Benzinga Insights

September 9, 10:40 AM

Upgrades

ADCT

1 minute read

Morgan Stanley Initiates Coverage On Vir Biotechnology with Underweight Rating, Announces Price Target of $15

By Benzinga Newsdesk

September 9, 8:07 AM

Morgan Stanley analyst Andrew Galler initiates coverage on Vir Biotechnology (NASDAQ:VIR) with a Underweight rating and announces Price Target of $15.

VIR